Payment overview · 2025
General Payments
$260.88
14 reported records · 9 companies
Healthcare provider profile · identity verified
Frank Benedict Marxer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1144229592
Verified facts
What the public records show
CMS Open Payments records show Frank Benedict Marxer, MD received $260.88 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.28 | 18.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.44 | 15.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.43 | 15.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.13 | 14.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.80 | 9.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.34 | 8.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.95 | 6.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.45 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.06 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.88 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.43 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 512 | 147 |
| Lisinopril | Lisinopril | 379 | 124 |
| Losartan Potassium | Losartan Potassium | 329 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 71 |
| Methylprednisolone | Methylprednisolone | 175 | 108 |
| Omeprazole | Omeprazole | 169 | 48 |
| Furosemide | Furosemide | 155 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 56 |
| Chlorthalidone | Chlorthalidone | 137 | 46 |
| Simvastatin | Simvastatin | 137 | 40 |
| Gabapentin | Gabapentin | 132 | 37 |
| Metformin Hcl | Metformin Hcl | 131 | 40 |
| Lorazepam | Lorazepam | 130 | 34 |
| Metformin Hcl Er | Metformin Hcl | 130 | 42 |
| Tramadol Hcl | Tramadol Hcl | 117 | 28 |
| Potassium Chloride | Potassium Chloride | 112 | 37 |
| Allopurinol | Allopurinol | 111 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 35 |
| Eliquis | Apixaban | 103 | 23 |
| Alprazolam | Alprazolam | 95 | 30 |
| Sertraline Hcl | Sertraline Hcl | 89 | 29 |
| Donepezil Hcl | Donepezil Hcl | 81 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 22 |
| Glimepiride | Glimepiride | 80 | 23 |
| Bupropion Xl | Bupropion Hcl | 74 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 68 | 24 |
| Spironolactone | Spironolactone | 67 | 22 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Synthroid | Levothyroxine Sodium | 59 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 15 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 15 |
| Atenolol | Atenolol | 52 | 15 |
| Clonidine Hcl | Clonidine Hcl | 52 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 22 |
| Finasteride | Finasteride | 50 | 17 |
| Montelukast Sodium | Montelukast Sodium | 49 | 18 |
| Carvedilol | Carvedilol | 47 | 18 |
| Cefdinir | Cefdinir | 47 | 43 |
| Azithromycin | Azithromycin | 45 | 35 |
| Famotidine | Famotidine | 42 | 15 |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 36 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 16 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Naproxen | Naproxen | 27 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 25 |
| Meloxicam | Meloxicam | 26 | 11 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Telmisartan | Telmisartan | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Baclofen | Baclofen | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.88 · 14 records | PFIZER INC. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, JARDIANCE, NEXLETOL, NURTEC ODT, PREVNAR 20, QULIPTA, SHINGRIX, TZIELD, UBRELVY, XIFAXAN, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error